📰 Gamida Cell News
Page 13 - Gamida Cell News Today
Fast, Ad-Free News Updates
Stay updated with breaking news from Gamida Cell. Real-time updates on events, politics, business and more.
August 31, 2022
Gamida Cell (GMDA) and Inhibikase Therapeutics (IKT) are two publicly traded equities with low current valuations and significant upside.
August 16, 2022
Gamida Cell has a key FDA approval pending which could shift the trajectory of the company and the stock. Click here for a full investment analysis.
August 15, 2022
Here are few names that would make logical acquisition targets for larger players.
August 15, 2022
GMDA earnings call for the period ending June 30, 2022.
August 1, 2022
(RTTNews) - Gamida Cell Ltd. (GMDA), on Monday, announced that the U.S. Food and Drug Administration or FDA has accepted for filing the companys ...
July 13, 2022
Wood's Ark Fund raised its stake in many Israeli companies in the second quarter and its portfolio includes non-tech companies.
June 25, 2022
GuruFocus Article or News written by GuruFocusNews and the topic is about:
June 8, 2022
/PRNewswire/ -- According to Coherent Market Insights, the global bone marrow transplant market is estimated to be valued at US$ 10,356.1 million in 2022 and...
June 8, 2022
/PRNewswire/ -- According to Coherent Market Insights, the global bone marrow transplant market is estimated to be valued at US$ 10,356.1 million in 2022 and...
June 6, 2022
Equities research analysts expect Gamida Cell Ltd. (NASDAQ:GMDA – Get Rating) to announce earnings of ($0.31) per share for the current fiscal quarter, Zacks reports. Zero analysts have made estimates for Gamida Cell’s earnings. The lowest EPS estimate is ($0.32) and the highest is ($0.29). Gamida Cell posted earnings per share of ($0.42) in the […]